BioSpace News Archive

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance® (empagliflozin) 10 mg.

BioSig Technologies, Inc., a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that it will host a live roundtable webinar to discuss the PURE EP 2.0 study results recently published in the Journal of Cardiovascular Electrophysiology.

Zogenix, a global biopharmaceutical company developing rare disease therapies, announced that members of its management team will participate in fireside chats at two upcoming investor conferences: the Stifel 2021 Virtual Healthcare Conference and Guggenheim Virtual 3rd Annual Neuro/Immunology Conference.

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it will participate in the 12th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 16, 2021, starting at 9:00 AM ET.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its financial and operating results for the three and nine months ended September 30, 2021, and provided a business update.

Vaxart, Inc. announced that Andrei Floroiu, President and CEO, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be participating in virtual fireside chats at the following conferences.

Align Technology, Inc. a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, announced that the company is scheduled to speak at upcoming financial conferences.

Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, provided an update on recent corporate developments and reported financial results for the three and nine months ended September 30, 2021.

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conferences.